版本:
中国

BRIEF-biOasis enters into a license agreement with Vaccinex Inc.

Sept 20 (Reuters) -

* biOasis enters into a license agreement with Vaccinex Inc.

* biOasis Technologies Inc - Says under terms of agreement, Vaccinex will have right to commercialize its anti-Semaphorin 4D antibody technology

* biOasis Technologies Inc - Under terms, Bioasis could receive up to $20 million in form of upfront and milestone payments

* biOasis Technologies Inc - Under terms of agreement, Vaccinex has been provided rights to transcend technology and its intellectual (patent) property Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐